Summary
A double-blind crossover study of the alphablocker Nicergoline was carried out in sixteen patients affected by benign prostatic bladder outflow obstruction. The “irritative” symptoms of prostatic hypertrophy, including nocturnal frequency and dysuria, were improved after Nicergoline significantly more than after placebo. In 10 further patients with prostatic hypertrophy, peak and mean flow rates increased by 50% and 77% respectively after the acute administration of Nicergoline. No side effects were detected. In conclusion Nicergoline seems to be active and well tolerated in the treatment of benign prostatic obstruction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcari G, Dorigotti L, Fregnan GB, Glasser AH (1960) Vasodilating and alpha receptor blocking activity of anewergoline derivactive. Br J Pharmacol 34:700
Boismare F, Lorenzo J (1975) Study of protection afforded by Nicergoline against the effect of cerebral ischemia in the cat. Arzneim Forsch 25:410
Boreham PF, Braithwaite P, Milewsky P, Pearson H (1977) Alpha adrenergic blockers in prostatism. Br J Surg 64:756
Caine M (1979) Can benign hypertrophy of the prostate be treated medically? Ann Urol 13:159
Caine M, Pfau A, Perlberg S (1976) The use of alpha adrenergic blockers in benign prostatic obstruction. Br J Urol 48:255
Caine M, Perlberg S, Meretyk S (1978) A placebo-controlled double blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 50:551
Caine M, Raz S, Zeigler M (1975) Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 47:193
Castro JE, Griffiths HJL, Edwards DE (1971) A double-blind controlled clinical trial of spironolactone for benign prostatic hypertrophy. Br J Surg 58:485
Farrar DJ, Prior JS (1976) The effect of bromocriptine in patients with benign prostatic hypertrophy. Br J Urol 48:73
Geller J, Nelson CG, Albert JD, Pratt C (1979) Effect of megestrol acetate on uroflow rates in patients with benign prostatic hypertrophy. Urology 14:467
Kaufman JJ, Goodwin WE (1959) Hormonal management of the benign obstructing prostate: use of combined androgenestrogen therapy. J Urol 81:165
Koch G (1972) The use of non parametric methods in the statistical analysis of the two period change-over design. Biometrics 28:577
Trimarchi F, Gelmi C, Marangoni R (1974) The alpha-adrenolytic action of Nicergoline studied by pupillography: effect on phenylephrine-induced mydriasis. IRCS Med Sci (Research on: clinical pharmacology and therapeutics; eye) 2:1640
Triulzi E, Devizzi S, Margonato A (1981) Use of Nicergoline in acute myocardial infarction with diastolic hypertension. II Farmaco—Ed Pr 36:449
Wallenstein S (1977) The analysis of the two period repeated measurements crossover design with application to clinical trials. Biometrics 261
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ronchi, F., Margonato, A., Ceccardi, R. et al. Symptomatic treatment of benign prostatic obstruction with Nicergoline: A placebo controlled clinical study and urodynamic evaluation. Urol. Res. 10, 131–134 (1982). https://doi.org/10.1007/BF00255955
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00255955